Jiangsu Topcel-kh Pharmaceutical Co., Ltd.

This early-stage study tests a new type of CAR-T cell therapy that has been 'armored' with an anti-PD1 feature to help it fight cancer better. It is for adults with diffuse large B-cell lymphoma that has come back or not responded to standard treatments. The main goals are to see…

This early-stage study is testing the safety and best dose of a new type of CAR-T cell therapy for adults with B-cell lymphoma that has returned or hasn't responded to other treatments. The therapy involves modifying a patient's own immune cells to target a protein called BAFF-R …